The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) ...
Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research ...
Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 ...
Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.
Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon ...
Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration selected enlicitide to receive the Commissioner’s National Priority Voucher (CNPV) in December ...
A novel treatment approach combining neoadjuvant immunotherapy with chemoradiation showed promising results in patients with locally advanced esophageal squamous cell carcinoma (ESCC), according to ...
Clinical Trials Arena on MSN
MSD boasts data for oral PCSK9 inhibitor as add on therapy
GlobalData’s patient-based forecast predicts that MSD’s enlicitide will achieve blockbuster status in 2031.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results